We next sought to obtain more information on the potential effect of myostatin inhibition in the less severe and more chronic forms of SMA, that is, Types II and III SMA, in whom combinatorial therapies could be envisioned. This evidence concerns the gene MSTN and proximal spinal muscular atrophy.